Marketing Agreement With Thermo Fisher Scientific To Expand Access To Precision Oncology
Jan 18 (Reuters) - Thermo Fisher Scientific Inc TMO.N :
* ONCOCYTE ANNOUNCES DEVELOPMENT AND CO-MARKETING AGREEMENT
WITH
THERMO FISHER SCIENTIFIC TO EXPAND ACCESS TO PRECISION ONCOLOGY
* ONCOCYTE CORP - AGREEMENT ALSO GRANTS ONCOCYTE RIGHTS TO
DEVELOP
FUTURE COMPANION DIAGNOSTICS ON GENEXUS SYSTEM
* ONCOCYTE CORP - ONCOCYTE WILL CLINICALLY VALIDATE THERMO
FISHER'S EXISTING ONCOMINE COMPREHENSIVE ASSAY PLUS ON GENEXUS
SYSTEM
Source text for Eikon: ID:nGNX2VvkY5
Further company coverage: TMO.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Insight Molecular Diagnostics
See all newsBrief: Insight Molecular Diagnostics Enters Amendment No. 2 To Merger Agreement On Sept 15, 2026
Insight Molecular Diagnostics Inc reports results for the quarter ended June 30 - Earnings Summary
Insight Molecular Diagnostics Inc expected to post a loss of 24 cents a share - Earnings Preview
Insight Molecular Diagnostics Q1 loss narrows as costs drop
Brief: Insight Molecular Diagnostics Completes Key Milestones Advancing Graftassuredx Toward FDA Submission